Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2628-2637

  Fregni, Giulia ^a   Perier, Aurélie ^a   Pittari, Gianfranco ^e   Jacobelli, Simon ^b   Sastre, Xavier ^c   Gervois, Nadine ^d   Allard, Mathilde ^d   Bercovici, Nadège ^a   Avril, Marie Franaĉoise ^a,b   Caignard, Anne ^a  

^a INSTITUT COCHIN   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSTITUT CURIE   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; LYMPHOCYTE RECEPTOR; NATURAL CYTOTOXICITY RECEPTOR; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKP46; PROTEIN DNAM 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CD3+ T LYMPHOCYTE; CD56+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; CASE-CONTROL STUDIES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SKIN NEOPLASMS; YOUNG ADULT;

EID: 79955518199     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2084     Document Type: Article

References (39)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70.
3. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008;26:955-62. (Pubitemid 351398090)
4. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24: 175-208.
5. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40. (Pubitemid 44297291)
6. Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260-5. (Pubitemid 41057741)
7. Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003;19:561-9. (Pubitemid 37311437)
8. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003;101:3052-7. (Pubitemid 36857995)
9. Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol 1998;161:400-8. (Pubitemid 28285548)
10. Moretta L, Moretta A, Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004;23:255-9. (Pubitemid 38294490)
11. Lanier L. Turning on natural killer cells. J Exp Med 2000;191:1259-62. (Pubitemid 30227114)
12. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009;206:1495-503.
13. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223. (Pubitemid 32368034)
14. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008;205:2965-73.
15. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159-66. (Pubitemid 43053538)
16. Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-9. (Pubitemid 28099678)
17. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH, et al. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-85. (Pubitemid 34293442)
18. Moretta L, Moretta A, Killer immunoglobulin-like receptors. Curr Opin Immunol 2004;16:626-33. (Pubitemid 39165891)
19. Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009;58:1517-26.
20. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003;24:603-9. (Pubitemid 37338529)
21. Lala PK, Elkashab M, Kerbel RS, Parhar RS. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. Int Immunol 1990;2:1149-58.
22. Hersey P, Hobbs A, Edwards A, McCarthy WH, McGovern VJ. Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients. Cancer Res 1982;42: 363-8. (Pubitemid 12207293)
23. Pittari G, Fregni G, Roguet L, Garcia A, Vataire AL, Wittnebel S, et al. Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients. Bone Marrow Transplant 2010;45:862-71.
24. Hüe S, Monteiro RC, Berrih-Aknin S, Caillat-Zucman S. Potential role of NKG2D/MHC class I-related chain A interaction in intrathymic maturation of single-positive CD8 T cells. J Immunol 2003;171: 1909-17. (Pubitemid 36966474)
25. Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau- Aubry A, et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 2006;177:3100-7. (Pubitemid 44277827)
26. Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, et al. Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 2004;109: 393-401. (Pubitemid 38252768)
27. Zhu J, Wang X, Xu X, Abassi YA. Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods 2006;309:25-33. (Pubitemid 43190799)
28. Konjević G, Mirjacić Martinović K, Vuletić A, Jović V, Jurisić V, Babović N, et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007;24:1-11. (Pubitemid 46569334)
29. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, et al. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS One 2009;4:e5597.
30. Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 2003;106:905-12. (Pubitemid 37071669)
31. Hersey P, Edwards A, McCarthy WH. Tumour-related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients. Int J Cancer 1980;25:187-94. (Pubitemid 10217390)
32. Farzad Z, Cochran AJ, McBride WH, Gray JD, Wong V, Morton DL, et al. Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res 1990;50:3585-8. (Pubitemid 20194099)
33. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, et al. NCRs and DNAM-1 mediateNK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119:1251-63.
34. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-86. (Pubitemid 35244469)
35. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, et al. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother 2009;59:215-30.
36. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13:98-107.
37. Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002;35:23-8. (Pubitemid 34028087)
38. Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004;84:493-501. (Pubitemid 41656477)
39. Azogui O, Avril MF, Margulis A, Guillard M, Caillou B, Prade M, et al. Tumor-infiltrating CD3-NKcells are more effective thanCD3+ T cells in killing autologous melanoma cells. J Invest Dermatol 1991;97:425-9.